CD47及其配体在肿瘤免疫治疗中的研究进展  

Research progress of CD47 and its ligands in tumor immunotherapy

作　　者：孔樱瑾 邢文婧[1] Kong Yingjin;Xing Wenjing(Department of Immunology,Harbin Medical University,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学基础医学院免疫教研室,哈尔滨150081

出　　处：《国际免疫学杂志》2023年第5期517-523,共7页International Journal of Immunology

基　　金：国家自然科学基金青年基金(81802867);黑龙江省普通本科高等学校青年创新人才培养计划(UNPYSCT-2015028);中国博士后科学基金面上项目(2018M641843);黑龙江省博士后科学基金(LBH-Z18205)。

摘　　要：CD47是一种广泛表达的免疫调节蛋白,通过与信号调节蛋白α(signal regulatory proteinα,SIRPα)、血小板反应素-1(thrombospondin-1,TSP1)和整合素等配体结合,调节细胞的迁移和吞噬活性,在维持免疫系统动态平衡中发挥重要作用。CD47在各类癌症中的过度表达往往与临床不良预后相关。封闭CD47可以抑制实体瘤及血液系统恶性肿瘤的生长,并提高常规化放疗及其他靶向治疗的疗效。文章就CD47在肿瘤增殖、侵袭及转移中的关键信号和相关靶向治疗进行综述,阐述了CD47与其配体在肿瘤进展中的作用及CD47相关药物的研究现状。CD47 is a widely expressed immunomodulatory protein,which regulates cell migration and phagocytosis by binding to ligands such as signal regulatory proteinα(SIRPα),thrombospondin-1(TSP1)and integrins.It plays an important role in maintaining the dynamic balance of the immune system.Overexpression of CD47 in all kinds of tumors is often associated with poor clinical prognosis.Blocking CD47 can inhibit the growth of solid and hematological malignant tumors,and improve the efficacy of conventional chemotherapy,radiotherapy,and other targeted therapy.This review summarizes the key signals and related targeted therapies of CD47 in tumor proliferation,invasion and metastasis,and elaborates on the role of CD47 and its ligands in tumor progression,as well as the research progress in CD47-related drugs.

关 键 词：CD47 肿瘤 免疫治疗 

分 类 号：R730.51[医药卫生—肿瘤]